Edition:
United States

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

4.27USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$4.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,007
52-wk High
$12.09
52-wk Low
$3.10

Chart for

About

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The... (more)

Overall

Beta: 1.09
Market Cap(Mil.): $79.65
Shares Outstanding(Mil.): 18.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Partner Therapeutics Acquires Leukine From Sanofi

* PARTNER THERAPEUTICS INC - HAS ACQUIRED GLOBAL RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE LEUKINE (SARGRAMOSTIM) FROM SANOFI

Feb 01 2018

BRIEF-Novelion Says U.S. District Court Judge Sentenced Unit Aegerion Pharmaceuticals

* NOVELION THERAPEUTICS INC - ANNOUNCED THAT A U.S. DISTRICT COURT JUDGE HAS SENTENCED NOVELION SUBSIDIARY AEGERION PHARMACEUTICALS

Jan 30 2018

U.S. judge sentences Novelion's Aegerion in drug marketing case

BOSTON A federal judge on Tuesday sentenced Aegerion Pharmaceuticals Inc for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the company's victims.

Jan 30 2018

UPDATE 1-U.S. judge sentences Novelion's Aegerion in drug marketing case

BOSTON, Jan 30 A federal judge on Tuesday sentenced Aegerion Pharmaceuticals Inc for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the company's victims.

Jan 30 2018

Novelion's Aegerion faces sentencing in U.S. drug marketing case

BOSTON, Jan 30 Aegerion Pharmaceuticals Inc is set to be sentenced on Tuesday for improperly marketing a cholesterol drug by a judge who rejected an initial plea deal and asked whether the drugmaker should be allowed to "collapse in disgrace."

Jan 30 2018

BRIEF-Novelion Therapeutics Announces Cost Reduction Plans, Capital Structure Review

* NOVELION THERAPEUTICS ANNOUNCES COST REDUCTION PLANS AND CAPITAL STRUCTURE REVIEW

Jan 24 2018

Novelion unit asks U.S. judge to approve plea deal, cites money woes

BOSTON Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty.

Dec 22 2017

Novelion unit asks U.S. judge to approve plea deal, cites money woes

BOSTON, Dec 22 Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty.

Dec 22 2017

BRIEF-Aspen Announces Strategic Partnership With CGB Diversified Services

* ASPEN ANNOUNCES STRATEGIC PARTNERSHIP WITH CGB DIVERSIFIED SERVICES

Dec 19 2017

BRIEF-Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics

* EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING Source text : http://bit.ly/2yOFk6N Further company coverage:

Dec 08 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥5,910 -68.00
Pfizer Inc. (PFE.N) $36.26 +0.55
Novartis AG (NOVN.S) CHF79.88 +0.20
Merck & Co., Inc. (MRK.N) $56.29 +0.30
Roche Holding Ltd. (ROG.S) CHF223.30 +0.15
Roche Holding Ltd. (RO.S) CHF226.60 +0.60
Bayer AG (BAYGn.DE) €98.20 +0.42
Bayer AG (BAYE.F) -- --
AstraZeneca plc (AZN.L) 4,728.00 +15.50
Allergan, Inc. (AGN.N) $164.04 -0.43

Earnings vs. Estimates